MicroRNA-135b promotes cancer progression by acting as a downstream effector of oncogenic pathways in colon cancer N Valeri, C Braconi, P Gasparini, C Murgia, A Lampis, V Paulus-Hock, ... Cancer cell 25 (4), 469-483, 2014 | 322 | 2014 |
Protective role of miR-155 in breast cancer through RAD51 targeting impairs homologous recombination after irradiation P Gasparini, F Lovat, M Fassan, L Casadei, L Cascione, NK Jacob, ... Proceedings of the National Academy of Sciences 111 (12), 4536-4541, 2014 | 218 | 2014 |
Integrated microRNA and mRNA signatures associated with survival in triple negative breast cancer L Cascione, P Gasparini, F Lovat, S Carasi, A Pulvirenti, A Ferro, H Alder, ... PloS one 8 (2), e55910, 2013 | 197 | 2013 |
microRNA classifiers are powerful diagnostic/prognostic tools in ALK-, EGFR-, and KRAS-driven lung cancers P Gasparini, L Cascione, L Landi, S Carasi, F Lovat, C Tibaldi, G Alì, ... Proceedings of the National Academy of Sciences 112 (48), 14924-14929, 2015 | 84 | 2015 |
miR-EdiTar: a database of predicted A-to-I edited miRNA target sites A Laganà, A Paone, D Veneziano, L Cascione, P Gasparini, S Carasi, ... Bioinformatics 28 (23), 3166-3168, 2012 | 29 | 2012 |
Use of microRNA (miR) expression profiling to identify distinct subclasses of triple-negative breast cancers (TNBC). CL Shapiro, L Cascione, P Gasparini, F Lovat, S Carasi, A Pulvirenti, ... Journal of Clinical Oncology 30 (15_suppl), 1007-1007, 2012 | 3 | 2012 |
Protective role of miR-155 in breast cancer through RAD51 targeting impairs homologous recombination after irradiation,(vol 111, pg 4536, 2014) P Gasparini, F Lovat, M Fassan, L Casadei, L Cascione, NK Jacob, ... PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF …, 2017 | | 2017 |
Micro-RNA signature differences in lung adenocarcinoma with specific driver alterations. L Landi, P Gasparini, S Carasi, C Tibaldi, L Cascione, G Ali', A D'Incecco, ... Journal of Clinical Oncology 31 (15_suppl), 11066-11066, 2013 | | 2013 |
Micro-RNA signature differences in lung cancer patients with ALK translocation, EGFR mutations and KRAS mutations. P Gasparini, L Landi, S Carasi, C Tibaldi, L Cascione, G Alì, A D'Incecco, ... Cancer Research 73 (8_Supplement), 3061-3061, 2013 | | 2013 |